Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Multicenter, Open-label Dose Escalation and Expansion Study of LOP628, Administered Intravenously in Adult Patients With cKit-positive Tumors and Acute Myeloid Leukemia

Trial Profile

A Phase I, Multicenter, Open-label Dose Escalation and Expansion Study of LOP628, Administered Intravenously in Adult Patients With cKit-positive Tumors and Acute Myeloid Leukemia

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LOP 628 (Primary)
  • Indications Acute myeloid leukaemia; Gastrointestinal stromal tumours; Lung cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 03 Apr 2018 Results of analysis trying to underline the mechanism of hypersensitivity reactions published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 28 Sep 2015 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 12 Mar 2015 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top